Medulloblastoma …

Roger J Packer MD

Neuro-Oncology

Updated 12.28.2023
Released 11.22.1993
Expires For CME 12.28.2026

Medulloblastoma

Author: Roger J Packer MD

See Contributor Disclosures

Medulloblastoma

In This Article

Quick Link

Introduction

Overview

Medulloblastoma is the most common malignant childhood brain tumor. There has been a marked improvement in overall survival for patients with this tumor, but a major challenge remains quality-of-life of survivors. There has also been an explosion in the understanding of the neurobiology of the tumor, and in this article, the author has attempted to capture the potential clinical significance of these new molecular discoveries, how they have significantly altered classification, how they will be incorporated into care, and the challenges that lie ahead.

Historical note and terminology

Medulloblastoma was introduced as a specific nosologic entity in 1925 by Bailey and Cushing (07). Twenty-nine patients were reported with a densely cellular, primarily small round cell tumor, of which 24 were located in the cerebellar vermis. Although initially considered a subtype of glioma and called "spongioblastoma cerebelli," the tumor was later renamed "medulloblastoma." Over the years, there has been considerable debate concerning the most appropriate classification for small round cell tumors of the posterior fossa. Rorke suggested that because histologically similar or identical tumors could be found in other regions of brain, especially the pineal region and cerebral cortex, it would be most reasonable to classify all small round cell tumors of the central nervous system as primitive neuroectodermal tumors and then subdivide them on the basis of location within the nervous system and other histological or clinical features, such as evidence for cellular differentiation (91). Based on biological data, there is clear evidence that the vast majority of small blue cell tumors that arise in the posterior fossa are molecularly different than those arising in other regions of the brain. For this reason, medulloblastoma is now considered an entity that only arises in the posterior fossa. The 2007 WHO classifications of tumors of the nervous system, medulloblastoma has been further subdivided into medulloblastoma and subtypes, including desmoplastic/nodular medulloblastoma; medulloblastoma with extensive nodularity; anaplastic medulloblastoma; and large-cell medulloblastoma (57). Cortical small cell tumors within the embryonal classification are now classified as embryonal tumors with subvarieties, including CNS neuroblastoma; medulloepitheliomas; and ependymoblastomas (58). Another tumor type, the atypical teratoid/rhabdoid tumor, is now considered a distinct biological entity. Tumors of the pineal region that resemble medulloblastoma histologically, termed “pineoblastoma,” are classified with tumors of the pineal region.

The most recent 2021 WHO classification of tumors of the central nervous system continues to build on the changes incorporated over the past decade. There is further incorporation of molecular changes, although the classification system does not recommend specific methods for molecular assessment. Immunohistochemical findings can be used. Methylome profiling, which uses arrays to determine DNA methylation patterns across the genome, has become a preferred method for molecular subclassification of embryonal and other tumors including medulloblastoma, but is not explicitly included in the 2021 classification. Classification has evolved into an integrated and layered diagnostic approach. Within the present classification system, four major molecularly defined subgroups of medulloblastoma are identified, which include: medulloblastoma, WNT-activated; medulloblastoma, SHH-activated and TP53-wild type; medulloblastoma, SHH-activated and TP53 mutant; and medulloblastoma non-WNT/non-SHH. Another classification subgroup is medulloblastoma, histologically defined. However, it is recognized that within these subgroups other molecular subdivisions may be important for clinical characterization; having prognostic value in this regard are multiple subtypes of WNT-associated medulloblastomas, the four or more subgroups of SHH medulloblastoma, and eight subgroups of the non-WNT/non-SHH medulloblastoma (11; 66; 95; 48; 97; 59; 113).

Table 1. Medulloblastoma

Medulloblastomas, genetically defined
	Medulloblastoma, WNT-activated Medulloblastoma, SHH-activated and TP53-mutant Medulloblastoma, SHH-activated and T53-wildtype Medulloblastoma, non-WNT/non-SHH
Medulloblastomas, histologically defined
(59)

Clinical manifestations

Presentation and course

Medulloblastoma, arising most commonly from the area of the cerebellar vermis, causes neurologic symptoms by filling the fourth ventricle and blocking cerebrospinal fluid egress or infiltrating cerebellar tissue. Approximately one third of patients have evidence of leptomeningeal spread at the time of diagnosis (16; 02). The time from onset of symptoms to diagnosis is usually 3 months or less (86). Occasionally, the tumor presents apoplectically, due to acute hemorrhage into the tumor with resultant obtundation, followed by coma.

The most common early symptoms of medulloblastoma are the nonspecific and nonlocalizing findings of increased intracranial pressure due to obstruction of the fourth ventricle. Papilledema, headaches, vomiting (especially morning vomiting), and lethargy are present in up to 90% of patients by the time of diagnosis (86). Ataxia is usually present early in the disease and results in truncal unsteadiness, which is later followed by appendicular cerebellar symptoms. Diplopia may be either secondary to pressure-related sixth nerve paresis or due to ocular motor dysfunction caused by direct infiltration of the tumor into the brainstem. Hyperreflexia secondary to ventricular dilatation is common, but corticospinal tract dysfunction is relatively infrequent. The tumor may invade the overlying meninges, and head tilt can be caused by herniation of the cerebellar tonsils or by meningeal irritation. Trochlear dysfunction with resultant head tilt is less common. In adults, medulloblastomas are more likely to arise laterally and cause seventh and eighth nerve dysfunction early in the course of illness.

As the tumor may affect extremely young children with unfused sutures, initial symptoms in children with congenital tumors may be relatively nonspecific and include anorexia, failure to thrive, and increased irritability. Macrocephaly, spread cranial sutures with an open and bulging fontanelle, and paralysis of upgaze (the "setting-sun" sign) are characteristic presentations in extremely young patients.

Despite the relatively frequent rate of leptomeningeal dissemination at the time of diagnosis, most patients with disseminated disease at the time of diagnosis do not have specific symptoms referable to leptomeningeal deposits. Occasionally, patients have back pain or radicular symptomatology due to tumor spread. Other symptoms of leptomeningeal spread, such as seizures, focal neurologic deficits, motor weakness, or spinal cord compression, are rare.

Prognosis and complications

Overall 5-year, disease-free survival for children with medulloblastoma ranges between 60% and 80% (14; 69). There is evidence that patients can be broadly separated into two prognostic subgroups (72; 27). Factors that have been found to be of prognostic importance include age at diagnosis, extent of surgical resection, local extent of tumor diagnosis, and extent of dissemination at diagnosis. Patients with so-called average-risk disease include those who are older (possibly greater than 7 years of age at time of diagnosis), those who have totally resected tumors that have not invaded the brainstem, and those who have no evidence of leptomeningeal dissemination at the time of diagnosis. Patients in the higher or less favorable risk group include those with disseminated tumor at the time of diagnosis, and possibly those who have had partially resected tumors or tumors that have invaded the brainstem at diagnosis (73; 02; 27; 01). A variety of molecular factors have been related to prognosis; however, they have been superseded by more expansive genomic analysis, including RNA expression, DNA methylation profiles, and DNA sequencing on both fresh frozen and formalin fixed tissue (28; 31; 47; 46; 79; 80). Such transcription findings can be combined with clinical parameters to create even more robust predictors of outcome (68; 37). Biological parameters such as nuclear beta-catenin staining and monosomy 6 (evidence of aberrant WNT signaling) are predictive of better outcome and elevated MYCC expression and amplification have been shown to be predictive of poorer outcome (64; 25; 67; 43; 68; 83; 105). TP53 mutation, which occurs primarily in SHH-driven and WNT-driven tumors, and connotes a poorer prognosis in SHH-driven tumors (120). Adding to the complexity is that even early childhood SHH medulloblastomas can be prognostically stratified (113), and possibly also the WNT-driven tumors (36).

A plethora of papers have been published over the past decade that have further divided medulloblastoma into multiple subgroups, often with differing prognosis (67; 46; 68; 48; 97). Even within the WNT subgroup, which as noted above is the group that has the best overall prognosis, molecularly-defined subgroups of patients have been noted in adults that carry less than a 100% survival rate (48). Four different molecular subgroups are now identified within the SHH grouping and the presence or absence of TP 53 mutation continues to be an important predictive factor, with wild type TP 53 tumors having a better prognosis. The eight subgroups, which have now been delineated predominantly by methylation profiling in the non-WNT/non-SHH pathway activated tumors have been shown to have different prognosis (97). Tumors within this subgroup that have MYC amplification and possible gain have a poorer prognosis, with less than 50% of patients surviving five years from diagnosis. In contradistinction, those tumors with specific chromosome losses, such as loss of chromosome 8 and 11, or chromosome gains (gain of chromosome 7), have an excellent prognosis. The presence of an isochromosome 17q, found predominately within the non-WNT/non-SHH activated tumors, has been associated with a poor prognosis in some studies, but not in all.

Clinical vignette

A 5-year-old boy developed unsteadiness associated with headaches and nausea 10 days before evaluation. In retrospect, the child had been complaining of mild headaches for six weeks. During the 24 hours before assessment, the child seemed sleepy and fell when he tried to walk.

On examination, the child was alert but irritable. He reported that he had a severe headache and vomited that morning on awakening. He had bilaterally reactive pupils but bilateral papilledema. Visual acuity and fields seemed to be intact. His face moved symmetrically, and the remainder of his cranial nerves was normal. When the child sat, there was marked truncal unsteadiness, and he reached with bilateral dysmetria. When he attempted to walk, he fell quickly to either side. Reflexes were diffusely increased.

Neuroimaging studies showed a large, somewhat hyperintense mass filling the fourth ventricle and causing marked hydrocephalus. The mass homogeneously enhanced. On MRI, the mass was decreased signal intensity on T1-weighted images and isointense on T2-weighted images. The mass seemed to be plastered to the back of the brain stem.

Biological basis

Etiology and pathogenesis

The etiology of medulloblastoma for the majority of children and adults remains unknown, but at least 10% and likely more can be linked to specific germ-line mutations. Inherited conditions that have been related to an increased risk of medulloblastoma include neurofibromatosis, Turcot syndrome, the nevoid basal cell carcinoma syndrome (Gorlin syndrome), and Li-Fraumeni syndrome. Identification of multiple cancer predisposition syndromes has raised concerns that many more patients with medulloblastoma may have germ-line mutations predisposing to development of medulloblastoma (119). As an example, heterozygous germline mutations in the G proteins-coupled receptor 161 (gpr161) were identified in approximately 3% of cases of SHH-activated medulloblastoma (09).

The likelihood of developing treatment-associated secondary tumors is a real issue for those with germ-line mutations, and this has led to a re-examination of treatment approaches, especially in those with SHH-driven tumors arising in patients who harbor an underlying P53 mutant germ line mutation (99; 119).

In the largest review to date, germ-line mutations possibly predisposing to tumor development were identified in 11% of 673 patients with medulloblastoma (116). Genes identified included APC, BRCA2, PALB2, PTCH1, SUFU, and TP53. Genetic predispositions varied in prevalence among medulloblastoma molecular subgroups and was highest for the sonic hedgehog subgroup, occurring in 20%; SUFU and PTCH1 accounted for the majority of predisposition in this subgroup. APC mutations were seen in the WNT subgroup.

Intra-utero irradiation has been related to an increased incidence of tumor development. Other environmental factors, such as drugs, nitroso-compounds, and electromagnetic fields, have been linked in some studies to the development of medulloblastoma, but data to support such associations are preliminary and equivocal. A history of measles immunization and SV40 exposure has been linked to development of medulloblastoma in one study (60; 87; 15).

There is extensive work to demonstrate that medulloblastoma, although made up predominantly of undifferentiated small round cells, frequently displays foci within the tumor of apparent differentiation along identifiable cellular lines. Neuronal and glial differentiation can be frequently identified utilizing immunohistochemical markers. A specific tumor marker for medulloblastoma still does not exist, although the majority of tumors will show synaptophysin expression. Histologic subvarieties of medulloblastomas have been identified, including the large cell variant and tumors with extensive nodularity, which may carry different prognosis (34; 23). In older children, the large-cell or anaplastic variant has been related to a poorer outcome (24). In younger children, especially infants, the desmoplastic or nodular histologic variant has been associated with better outcome (34).

Detailed genetic investigations have disclosed reproducible genetic abnormalities in medulloblastoma, and these findings have been critical in improving understanding of the disease and suggesting potential means of more precise, effective treatment (81; 102; 78; 37). Amplification and overexpression of MYCC and MYCN has been associated with poorer survival (31).

Based on molecular genetic findings, the four main subgroups of medulloblastoma have been identified, and molecular subclassification provides further understandings concerning cellular origin, biological mechanisms, underlying tumor development, and prognosis. These subgroups are WNT, sonic hedgehog (SHH), group 3, and group 4 (sometimes considered as one subgroup, non-WNT/non-SHH) (24; 31; 92; 110; 47; 79; 25; 67; 103; 43; 46; 68; 94; 105; 85; 120; 45; 89; 84; 100; 95; 11; 37; 40; 97). TP53 and OTX2 have been related to poorer outcome (36).

The WNT subgroup comprises approximately 10% of all medulloblastomas and is characterized by a WNT signaling gene expression signature and beta-catenin nuclear staining. The developmental origin of the WNT subset, which occurs predominantly in older children, adolescents, and young adults, is believed to be from the embryonal rhombic lip region (25; 11; 97). These tumors are usually classical medulloblastoma by histology, but they may infrequently be large cell or anaplastic variants. They are usually not disseminated at time of diagnosis. The WNT tumors most commonly have CTNNB1 mutations, and in the 5% to 10% that do not, the remaining majority has APC mutations. Such APC mutations are usually associated with a germline APC mutation, and children may have stigmata of Turcot syndrome. The WNT medulloblastomas characteristically show 6q loss (monosomy 6), but this may not present in patients older than 18 years of age with WNT tumors. This is the subtype of medulloblastoma with the best prognosis. In those less than 21 years of age, 90% or greater of patients are cured after appropriate treatment (79; 11; 66; 97).

The sonic hedgehog (SHH) variants of medulloblastoma, in total, make up approximately 25% of all medulloblastomas (25; 95; 90). Embryologically, these tumors are believed to emanate from the external granular layer of the cerebellum. Genetically, they are characterized by chromosome 9 deletions, and mutations may occur at multiple sites along the SHH pathway, including PTCH1, PTCH2, SMO, SUFU, and GLI2. Germline mutations occur in the SHH-subgroup including mutations in GPR161 in very young children and Li-Fraumeni syndrome (90; 09). Sonic hedgehog medulloblastomas tend to be bimodal and occur in infants and younger children (those less than 3 years of age), and then in adulthood. However, they may arise in children over 3 years of age, and children in the older childhood subgroup have the worst prognosis.

The most common subsets of SHH-driven medulloblastoma arise in children younger than 3 years of age and are SHH-β and SHH-γ. The SHH-β form is more frequently metastatic. The SHH-γ form, which has the best prognosis, is histologically characterized by extensive nodularity. In SHH-β, SMO mutations tend to be associated with a favorable prognosis, whereas SUFU mutations have a less favorable one. PTCH1 mutations can be seen both in subgroup SHH-β and SHH-γ.

In older children, subtype SHH-α is more likely to occur and is hallmarked by MYCN and GLI2 amplifications. SHH-α medulloblastomas have also frequently associated tp53 mutations and carry a poor prognosis, as 40% or less of children survive after treatment. The fourth SHH subtype termed SHH-δ underlies the majority of adult cases, and in this subgroup, both PTCH1 and SMO mutations can occur.

The non-WNT/non-SHH activated subtype of medulloblastoma, which includes previously named group 3 and group 4 in total, makes up the majority of cases of medulloblastoma. Group 3 medulloblastomas comprises approximately 25% of all medulloblastomas cases, whereas group 4 medulloblastomas makes up approximately 40%. The origins of non WNT/non SHH were unknown until the recognition that atypical cells that reside in the persistent rhombic lip-PeRLs act as a premalignant process and can transform into non WNT/non SHH medulloblastomas (39). There is a male predominance for non-WNT/non-SHH activated tumors. Non-WNT/non-SHH activated tumors with MYC-amplification are a well-recognized subset (11; 97). Within the non-WNT/non-SHH subgroup, there have been further subdivisions identified in addition to those with MYC amplification.

As noted previously, MYC-amplification is frequently present in group 3 medulloblastomas, and when present it connotes poor prognosis. Isochromosome (i17q) is seen in non-WNT/non-SHH medulloblastomas. Although different classification systems have suggested somewhat differing subdivisions, non-WNT/non-SHH tumors have been recognized to be comprised of eight different molecular subgroups by methylation array testing (97). These subgroups are identified by activation of various genes, including tandem duplication of SNCAIP gene with resultant activation of PRDM6 by enhancer high-jacking, MCYN amplification, and GFI1 or GFI1B overexpression. Some of the subgroups have been fairly definitively shown to have specific prognosis, for example, chromosome 11 loss has been associated with an excellent prognosis, whereas other subgroups have been shown to connote not only a poorer prognosis, but also a tendency for late relapse.

Table 2. Simplified Biological Stratification of Medulloblastoma (105; 97)

Subtype	Group 1/WNT	Group 2/SHH	Group 3	Group 4
Pathway Activated	WNT	SHH	?	?
Percent Affected	10% to 15%	20% to 25%	15% to 25%	25% to 50%
Genetics	CTNNBI mutation; 90%; monosomy 6; APC mutations (< 10%)	Chromosome 9; PTCH1/SMO/SUFU in infants, adults Mutation PTCH: Gli amplification in children, adolescents; p53 mutation MYCN+	MYC amplification Amplification; 17 chromosome abnormality	MYCN amplification; CDK6 amplification; 17q chromosome abnormality
Histology	Classical; rarely anaplastic	Desmoplastic/nodular in infants; some classical	Classical and anaplastic	Classical and anaplastic
Clinical Features	Older child/adult; usually non-disseminated	Infants and older children/adults bimodal; children less common	Greater male>female; infants and childhood; frequently disseminated	All ages; may be disseminated
Prognosis	Excellent	Excellent in infants; children/adults poor good to intermediate	Poor with MYC amplification	Intermediate to poor
	Possible worse with OTX or TP53 mutations
* Now classified as part of non-WNT/non-SHH activated subset.

Diagnostic workup

If a posterior fossa tumor is thought likely, initial diagnostic workup usually consists only of either a CT or MRI, performed with and without contrast enhancement (121). Both procedures are 95% to 100% reliable in demonstrating the presence of the tumor. On CT scans, medulloblastomas are usually isodense or hyperdense masses that enhance readily after contrast. Although the enhancement is usually homogeneous, heterogeneous enhancement may be present. There may be associated hemorrhage, calcifications, and, less frequently, cystic changes within the tumor. Associated hydrocephalus occurs in over 80% of cases. On MRI, medulloblastoma is usually well visualized. The tumor tends to be of decreased signal intensity on T1-weighted images and hypo- or iso-intense on T2-weighted images.

Medulloblastoma (MRI) (1)

The infiltrative nature of the tumor in this 12-year-old boy is evident in this T2-weighted MRI. (Contributed by Dr. Sherman Stein.)
Medulloblastoma (MRI) (2)

Imaging from a 9-year-old girl who presented with acute onset of headaches and vomiting reveals a well-circumscribed mass along the midline of the posterior fossa. The mass fills the 4th ventricle and effaces the vermis. The mass ...

Tumor extent, especially infiltration into the brainstem and extension through the foramen magnum, is appreciated better on MRI than on CT. As in the case of CT, the post-contrast scan usually shows extensive homogeneous or, less commonly, heterogeneous enhancement. Increased tumor vascularity is often present. Results with MRI spectroscopy demonstrate that the tumor usually has biochemical changes similar to those described in patients with malignant gliomas.

In stable patients, evaluation for extent of dissemination can be useful prior to surgery. Spinal MRI, with and without gadolinium, demonstrates evidence of leptomeningeal disease in 20% to 50% of patients.

Drop metastases in primitive neuroectodermal tumor (MRI)

In this sagittal, enhanced, T1-weighted MRI scan of the spine, the spinal canal (blue) is filled inferiorly with tumor (red arrows), metastatic from the brain (via the CSF). (Contributed by Dr. Sherman Stein.)

Following histological confirmation, extent of disease evaluation is indicated in all patients to help in treatment planning (72). MRI of the entire neuro-axis, preferably performed prior to surgery to avoid postoperative artifacts, is optimal to access for disease dissemination (69). Cerebrospinal fluid cytological examination is also indicated, as it provides complimentary evidence for tumor dissemination (30). The utility of bone scans and bone marrow examinations in the evaluation of extent of disease remains unproven and is now rarely done. If there are roles for such examinations, they should probably be limited to children younger than 3 years of age who are widely disseminated throughout the neuroaxis at diagnosis and may be at highest risk for systemic dissemination.

Molecular subclassification by a variety of different genetic techniques are now required for optimal medulloblastoma subclassification and disease risk stratification (80; 98; 58). Such molecular findings are increasingly used to guide therapy.

Management

At present, management for children with medulloblastoma is based on postoperative disease stratification and increasing molecular subgrouping. Surgery is the initial step in treatment, and gross total resection is possible in over 75% of patients. Surgery may be complicated by direct brain stem or cerebellar injury, post-operative infection or post-operative cerebellar mutism syndrome. The latter is the delayed onset of mutism, a few hours after surgery, and emotional liability, often associated with hypotonia, cerebellar dysfunction, and supranuclear palsies. Thought to be related to dentate thalamocortical damage, due partially to cerebellar vermian damage, it occurs in nearly 25% of children and results in permanent sequelae in approximately one half of those affected (88). Most studies report more favorable outcome after extensive resections, and patients whose tumors are only biopsied rarely survive. Although gross total resection has been related to improved outcomes, this association is attenuated by molecular subgroup affiliation (109). There is little evidence that overall survival is better after gross total resection as compared to “near-total” resection. Surgery alone is never adequate treatment.

Stratification into risk groups, following surgery, is the next critical component of management. The coupling of clinical staging information with molecular results is quickly becoming the standard for risk stratification children with medulloblastoma (31; 25; 46; 66). As noted previously, clinical staging includes evaluation for extent of disease by both imaging of the entire neuroaxis by MRI and lumbar cerebrospinal fluid cytological examination. MRIs of the spine can be difficult to interpret following surgery due to blood clots and other postoperative changes, and for these reasons, MRI of the entire neuroaxis is best performed prior to surgery. In addition, assessment of the amount of residual disease present after surgery and the presence of extensive anaplasia on microscopy are factors that are usually included in clinical risk stratification. Conventionally, patients have been separated into those with average-risk disease, which is defined as total or near total resection (less than 1.5 cm2 of residual disease following surgery), nonanaplastic histology, and no evidence of tumor dissemination. Those with high or poor-risk disease have potentially detrimental findings including greater than 1.5 cm2 residual disease, disseminated disease either seen on MRI scan or confirmed by positive cerebrospinal fluid cytological examination for tumor cells, or anaplastic histology (greater than 50% of the tumor is anaplastic). Molecular findings that would result in patients being considered to be in the higher risk disease categorization are somewhat influx, although there is consensus that non-WNT/non-SHH activated medulloblastomas with MYC amplification connotes poor risk, as well as those SHH-activated tumors, which harbor concomitant p53 mutation. Other molecular findings have not yet been routinely included in risk stratification determination.

The concept of very good risk patients, mainly those with WNT-activated tumors without tumor dissemination at the time of diagnosis and those patients with group 4 tumors with chromosome 11 loss, has been accepted (11; 76; 97). Conversely, patients with widely disseminated disease, SHH-activated tumors with concomitant p53 mutation, or MYC-amplified group 3 tumors are considered very high risk (11; 97). Such combined clinical and molecular characterizations are the backbones of ongoing studies, as well as newly developed prospective clinical trials.

The backbone of postsurgical treatment is craniospinal radiation therapy with supplemental local boost radiotherapy (72; 41; 27). Conventional treatment consists of 3600 cGy of craniospinal radiotherapy and local boost therapy up to a total posterior fossa dose of 5580 cGy. There is no clear evidence that hyperfractionated radiation therapy improves outcome (82). For children with average-risk disease, craniospinal radiotherapy may be sufficient for disease control; the best reported long-term survival rates range between 55% and 70% at five years. In addition, the doses of radiotherapy required for disease control may cause significant sequelae. In a randomized trial, a reduction of the craniospinal radiotherapy from 3600 to 2340 cGy in patients with localized disease at diagnosis was found to be ineffective, as a higher rate of leptomeningeal disease relapse and a lower rate of overall disease-free survival occurred in patients receiving the lower dose of radiotherapy (17). However, an update of this study showed the differences in survival between the two arms to have narrowed (108). Also, in a prospective randomized study performed by the International Society of Pediatric Oncology, no difference was found in survival of nondisseminated patients treated with reduced-dose radiotherapy as compared to conventional-dose therapy (06). In another International Society of Pediatric Oncology study, pre-irradiation chemotherapy with vincristine, VP16, and carboplatin resulted in better progression-free survival (but not overall survival) than treatment with 3600 cGy of craniospinal RT alone (106). Delays in the completion of radiotherapy detrimentally affect outcome (106; 05; 117).

To try to reduce sequelae secondary to the scatter of craniospinal radiation to other organs, a variety of approaches such as intensity-modulated radiotherapy and proton-bean radiotherapy have been used, with preliminary results demonstrating a reduction in radiation exposure to organs, such as the heart and liver, without a deterioration in the rate of tumor control (75; 77; 96; 22).

A prospective, randomized trial has compared two forms of adjuvant chemotherapy and reduced doses of radiotherapy (2340 cGy) in an attempt to both improve survival for children with average-risk disease and reduce sequelae. This was partially based on one study in 68 children demonstrating approximately an 80% event-free survival after treatment with 2340 cGy of craniospinal radiotherapy and adjuvant, post-radiotherapy lomustine, vincristine, and cisplatinum chemotherapy (70). The results of the randomized trial of 421 children between 3 and 21 years of age demonstrated a 5-year event-free survival of 81% (69). Another study using the same dose of radiotherapy and high-dose chemotherapy demonstrated similar outcomes (29). One pilot study demonstrated a 70% (plus or minus 20%) 5-year disease-free survival rate when even further reduced craniospinal radiotherapy was coupled with chemotherapy in 10 patients (35). In addition, lower cumulative doses of post-radiotherapy cisplatin have not been associated with poorer rates of disease control (65).

In 2021, the results of the Children’s Oncology Group study comparing 1800 cGy of craniospinal radiation to 2340 cGy of craniospinal radiation in children between 3 and 7 years of age with nondisseminated, nonanaplastic medulloblastoma with less than 1.5 cm² of residual disease after surgery was reported (63). In this trial, which randomized over 500 children, treatment with the reduced dose of craniospinal radiation (1800 cGy) was associated with inferior progression free survival and a higher rate of disseminated relapse than seen in patients treated with standard 2340 cGY of craniospinal radiation. Although this study was not statistically powered for molecular stratification, group 4 patients had the poorer survival with the reduced dose of craniospinal radiation. It should, however, be noted that within the subgroup of children between 3 and 7, the reduction of the craniospinal radiation dose was associated with improved neurocognitive outcome. In the same study, all patients between 3 and 21 years of age were randomized between whole posterior fossa and tumor only with a margin boost radiation therapy. Progression free and overall survival were found to be equivalent within the two radiation boost subgroups. An interesting finding that needs to be confirmed in a larger population is those patients with SHH-pathway activated tumors had possibly better overall progression free survival with the more restrictive radiation boost. Because germline predisposition testing was not done routinely in the study, these results are difficult to interpret, but one possibility is the lower volume of boost radiation therapy was associated with better outcomes in children with germline mutations underlying their SHH tumors because the “late relapsers” in the SHH group were not medulloblastoma relapses but rather radiation-induced secondary high-grade tumors occurring in regions in the larger radiation-boost posterior fossa fields.

In another recently completed Children’s Oncology Group study also reported in 2021, children between the ages of 3 and 21 years of age with high-risk medulloblastoma were randomized to receive either carboplatin or no carboplatin during radiation therapy on a daily basis (55). Both arms of patients in the study continued to receive vincristine during radiotherapy. Although there was not a difference in progression-free and overall survival for the study as a whole, those children with group 3 tumors (on post-HOC evaluation) receiving carboplatin during therapy had better progression-free survival than those who did not receive carboplatin. Another part of this prospective randomized study evaluated the addition of retinoic acid following completion of radiation; this randomization did not show a difference in survival or progression-free survival in those who did or did not receive retinoic acid.

For patients with high-risk disease, there is evidence that adjuvant chemotherapy is of benefit. Although responses can be seen after pre-irradiation chemotherapy, there is no evidence that such approaches improve survival (52; 50; 118; 32; 62; 107). In a Children's Cancer Group Study, patients treated with pre-irradiation 8-in-1 therapy had poorer survival rates than those receiving chemotherapy after radiation, raising the question of whether delay of radiotherapy results in poorer overall disease control (01). A study by the German Society of Pediatric Hematology-Oncology also demonstrated poorer survival if pre-radiation chemotherapy was given in average-risk patients, but there was no survival difference in high-risk patients (49).

Another approach is to utilize radiation at a higher total dose, but deliver it in a different dose fraction sequence—hyperfractionated accelerated radiation therapy. Its use has not been demonstrated to result in clear-cut survival benefits for patients (61; 44). Follow-up studies for those treated with hyperfractionated accelerated radiotherapy and thiotepa demonstrated a subgroup of children who developed white matter changes not usually seen after standard radiotherapy (112). Such changes suggest a higher likelihood of long-term neurocognitive sequelae and may be confused with tumor recurrence. Even another approach is the use of chemotherapy after initial tumor biopsy, in an attempt to shrink the tumor prior to definitive surgery (38) and make subsequent surgery more extensive and less hazardous.

For children younger than 3 years of age with non-SHH activated medulloblastoma, standard treatment carries with it an extremely high risk of significant long-term intellectual sequelae. Combinations such as MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) and the 4-drug regimen of cyclophosphamide, cisplatinum, VP-16, and vincristine have shown the ability to control disease in subsets of patients following surgery without the use of radiotherapy (19). Approximately 40% of children with medulloblastoma treated with chemotherapy alone will have stable disease while receiving chemotherapy. This is especially true for those children with totally resected, nondisseminated tumors prior to the initiation of treatment. More aggressive regimens may be more effective, including those utilizing autologous stem cell rescue (33; 111; 20). Some evidence suggests that those patients with a complete response to chemotherapy may not require radiotherapy (33; 101; 111; 90). Studies have also shown that methotrexate given intraventricularly and systemically at high doses may improve survival for infants and obviate the need for radiotherapy (92). However, such an approach may cause additive neurotoxicity. Also, in relapsed patients with local disease, long-term salvage has been reported after re-treatment with high-dose chemotherapy and local radiotherapy (21). Still, other approaches include the addition of local radiotherapy to the primary tumor site following chemotherapy in those children with nondisseminated disease and the use of intrathecal mafosfamide, a pre-activated form of cyclophosphamide (04; 10). The latter two approaches have not clearly improved outcome.

Significantly better survival rates have been seen in infants and young children (arbitrarily less than 3 or 4 years of age dependent on study) with SHH-activated medulloblastoma treated with chemotherapy alone. Progression-free and overall survival rates of 75% have been obtained after treatment with high-dose chemotherapy with stem-cell rescue or with regimens that have included both intravenous methotrexate and/or intrathecal chemotherapy. Treatment with a regimen that did not include methotrexate or intrathecals was not as successful (90; 54).

Outcomes

Reported progression-free and overall survival rates for patients with medulloblastoma have risen over the past two decades. This is likely due to multiple factors including the widespread use of cisplatin-based adjuvant chemotherapy regimens and the conventional acceptance of the extensive primary site resection as a critical component of treatment. For children greater than three years of age with average-risk disease after treatment with craniospinal and local boost radiotherapy and adjuvant chemotherapy, during and after radiation therapy, expected 5-year progression-free survival rates of greater than 75% or greater have been documented (29; 69). The majority of patients surviving greater than five years from diagnosis are “cured” of their disease. However, late relapse may occur. Late failures have to be carefully separated from the development of secondary tumors. Even for those patients with poor risk disease after treatment with both craniospinal and local boost radiotherapy and chemotherapy, 5-year progression free survival rates between 50% and 65% have been reported (42).

As noted previously, there may be subgroups of patients greater than three years of age who carry an even better survival rate, such as those children with WNT-driven tumors, with survival rates which exceeds 90%. In contradistinction, children with MYC-amplified group 3 tumors and those with p53 mutated SHH tumors have a much poorer prognosis, with survival rates of 40% or less five years from diagnosis. Similarly, children with wide spread disseminated disease carry a poor prognosis.

For children less than three years of age, prognosis is not as favorable as noted in older children, either because of biological differences between tumors in older and younger patients or because of the reluctance to use craniospinal radiation therapy in the younger children. However, for those with SHH tumors without concomitant p53 mutation, treatment with chemotherapy, especially aggressive chemotherapy utilizing drugs at high doses (supplemented by bone marrow or autologous stem cell rescue) or intrathecal chemotherapy, has a relatively favorable prognosis, as 75% or greater of patients can be expected to be alive five years from diagnosis (38; 93; 13). The prognosis of infants and children less than three years of age treated with chemotherapy alone with non-SHH driven tumors is less favorable, ranging from 25% to 50% (38; 10; 13; 54).

The follow-up posttreatment for children with medulloblastoma is relatively standardized. There is consensus that posttreatment MRI scanning of the brain and spine are indicated, usually every three months for the first two to three years after treatment, and then at a less frequent interval (6 months) until five years from diagnosis or end of treatment. The need for routine cerebrospinal fluid monitoring in children without evidence of dissemination at diagnosis is less clear. “Liquid biopsy,” assessing for cell-free DNA in cerebrospinal fluid, is a promising technique; if found to be a reliable means to detect early relapse prior to MR detection, it will dramatically alter the timing and need for cerebrospinal fluid assessment (26; 56).

The sequelae of treatment for children with medulloblastoma are significant. Although surgery is usually well tolerated for the majority of the patients, with relatively few patients having significant long-term, surgically related morbidity, some patients develop a poorly understood postsurgical syndrome of cerebellar mutism, obtundation, and severe motor dysfunction (12; 18). Craniospinal radiotherapy has been related to the development of significant intellectual and endocrinological long-term deficits (71). Intellectual deficits, including declines in overall intelligence and more selective dysfunctions, such as memory deficits, speech dysfunction, visual-spatial abnormalities, and attention difficulties, are progressive and more common in younger patients. Chemotherapy may also cause sequelae. As an example, cisplatinum may cause audiologic dysfunction (65). Overall, survivors of medulloblastoma commonly have life-altering neurologic, neurocognitive, and psychosocial sequelae (03).

Late failures may occur in children with medulloblastoma, but need to be carefully separated from secondary tumors. Secondary tumors, including the development of glioblastoma multiforme and leukemia, are being increasingly reported (74; 08). The benefits of surveillance testing are still being debated, although most still recommend routine follow-up studies for at least five years after diagnosis (51; 114). Primary relapse may occur outside the nervous system, especially in patients who have received postsurgery radiotherapy without adjuvant chemotherapy (104). When relapse occurs, independent of it occurring “early” or “late” after diagnosis, medulloblastoma molecular subtypes remain stable, although with time the tumor gains other mutations, making treatment of recurrence difficult (115).

Media

References

01: Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 1996;38(2):265-71. PMID 8869053
02: Allen JC, Bloom J, Ertel I, et al. Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. Semin Oncol 1985;13:110-22. PMID 3513315
03: Armstrong GT, Jain N, Liu W, et al. Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro Oncol 2010;12(11):1173-86. PMID 20716593
04: Ashley DM, Merchant TE, Strother D, et al. Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: children’s oncology group study P9934. J Clin Oncol 2012;30(26):3181-6. PMID 22851568
05: Back M, Ahern V, Berry M, et al. Importance of radiation time and dose factors on outcome for childhood medulloblastoma. Australas Radiol 2005;49:298-303. PMID 16026436
06: Bailey CC, Gnekow A, Wellek S, et al. Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SOP) and the (German) Society of Paediatric Oncology (GPO): SIOP 2. Med Pediatr Oncol 1995;25:166-78. PMID 7623725
07: Bailey P, Cushing H. Medulloblastoma cerebelli, a common type of mid-cerebellar glioma of childhood. Arch Neurol Psychiatry 1925;14:192-224.
08: Baliga S, Gallotto S, Bajaj B, et al. Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy. Neuro Oncol 2022;24(6):1010-9. PMID 34788463
09: Begemann M, Waszak SM, Robinson GW, et al. Germline GPR161 mutations predispose to pediatric medulloblastoma. J Clin Oncol 2020;38(1):43-50. PMID 31609649
10: Blaney SM, Kocak M, Gajjar A, et al. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol 2012;109(3):565-71. PMID 22790443
11: Cavalli FM, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 2017;31(6):737-54.e6. PMID 28609654
12: Cochrane DD, Gustavsson B, Poskitt KP, et al. The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood. Pediatr Neurosurg 1994;20(10):19-29. PMID 8142278
13: Cohen BH, Geyer JR, Miller DC, et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children's Oncology Group. Pediatr Neurol 2015;53(1):31-46. PMID 26092413
14: David KM, Casey AT, Hayward RD, Harkness WF, Phipps K, Wade AM. Medulloblastoma: is the 5-year survival rate improving. J Neurosurg 1997;86:13-21. PMID 8988076
15: de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol 2008;10(6):1040. PMID 18676356
16: Deutsch M, Reigel DM. Myelography and cytology in treatment of medulloblastoma. Int J Radiat Oncol Biol Phys 1981;7:721-5. PMID 7287532
17: Deutsch M, Thomas PR, Krischer J, et al. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children’s Cancer Group-Pediatric Oncology Group Study. Pediatr Neurosurg 1996;24(4):167-76; discussion 176-7. PMID 8873158
18: Doxey D, Bruce D, Sklar F, Swift D, Shapiro K. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg 1999;31(3):131-6. PMID 10708354
19: Duffner P, Horowitz ME, Krishner JP. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328:1725-31. PMID 8388548
20: Dufour C, Kieffer V, Varlet P, et al. Tandem high‐dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high‐risk medulloblastoma or supratentorial primitive neuro‐ectodermic tumors. Pediatr Blood Cancer 2014;61(8):1398-1402. PMID 246649378
21: Dupuis-Girod S, Hartmann O, Benhamou E, et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma. J Neurooncol 1996;27:87-98. PMID 8699230
22: Eaton BR, Esiashvili N, Kim S, et al. Clinical outcomes among children with standard-risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys 2016;94(1):133-8. PMID 26700707
23: Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94(2):552-60. PMID 11900240
24: Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63(5):441. PMID 15198123
25: Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011;29(11):1400-7. PMID 20921458
26: Escudero L, Llort A, Arias A, et al. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nat Commun 2020;11(1):5376. PMID 33110059
27: Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma: the results of a prospective randomized trial of radiation therapy with and without chloroethylcyclohexyl nitrosourea, vincristine and prednisone. J Neurosurg 1990;72:572-82. PMID 2319316
28: Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004;22:994-8. PMID 14970184
29: Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7(10):813-20. PMID 17012043
30: Gajjar A, Fouladi M, Walter AW, et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 1999;17(6):1825-8. PMID 10561221
31: Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncology 2004;22:984-93. PMID 14970185
32: Gentet JC, Dox F, Bouffet E, et al. Carboplatin and VP-16 in medulloblastoma: a phase 2 study of the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 1994;23(5):422-7. PMID 8084309
33: Geyer JR, Jennings M, Sposto R, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol 2005;23:7621-31. PMID 16234523
34: Giangaspero F, Perilongo G, Fondelli MP, et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 1999;91(6):971-7. PMID 10584843
35: Goldwein JW, Radcliffe JR, Johnson J, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996;34:899-904. PMID 8598368
36: Goschzik T, Mynarek M, Doerner E, et al. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas. Acta Neuropathol 2022;144(6):1143-56. PMID 36181537
37: Goschzik T, Schwalbe EC, Hicks D, et al. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncol 2018;19(12):1602-16. PMID 30392813
38: Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. The Lancet 2005;6:573-80. PMID 16054568
39: Hendrikse LD, Haldipur P, Saulnier O, et al. Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature 2022;609(7929):1021-8. Erratum in: Nature 2022;612(7940):E12. PMID 36131014
40: Hwang EI, Kool M, Burger PC, et al. Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: a report from the Children's Oncology Group randomized ACNS0332 trial. J Clin Oncol 2018:JCO2017764720. PMID 30332335
41: Hughes EN, Shillito J, Sallan SE, Loeffler JS, Caasady JR, Tarbell NJ. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 1988;61(10):1992-8. PMID 3129177
42: Jakacki RI, Burger PC, Zhou T, et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children’s Oncology Group Phase I/II study. J Clin Oncol 2012;30(21):2648-53. PMID 22665539
43: Jones DT, Jäger N, Kool M et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012;488(7409):100-5. PMID 22832583
44: Kennedy C, Bull K, Chevigard M, et al. Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. Int J Rad Oncol Biol Phys 2014;88(2):292-300. PMID 24239386
45: Kool M, Jones DT, Jager N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibitor. Cancer Cell 2014;25(3):393-405. PMID 24651015
46: Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012;473-84. PMID 22358457
47: Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008:3(8):e3088. PMID 18769486
48: Korshunov A, Sahm F, Zheludkova O, et al. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. Neuro Oncol 2019;21(2):214-21. PMID 30252101
49: Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000;46(2):269-79. PMID 10661332
50: Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 1990;8(2):330-6. PMID 2153766
51: Kramer EH, Vezina LG, Packer RJ, Fitz CR, Zimmerman RA, Cohen MD. Staging and surveillance of children with central nervous system neoplasms: recommendations of the Neurology and Tumor Imaging Committees of the Children’s Cancer Group. Pediatr Neurosurg 1994;20(4):254-62; discussion 262-3. PMID 8043464
52: Kretschmar CS, Tarbell NJ, Kupsky W, et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J Neurosurg 1989;71:820-5. PMID 2585072
53: Kuijten RR, Bunin GR. Risk factors for childhood brain tumors. Cancer Epidemiol Biomarkers Prev 1993;2(3):277-88. PMID 8318881
54: Lafay-Cousin L, Bouffet E, Strother D, et al. Phase II study of nonmetastatic desmoplastic medulloblastoma in children younger than 4 years of age: a report of the Children's Oncology Group (ACNS1221). J Clin Oncol 2020;38(3):223-31. PMID 31774708
55: Leary SES, Packer RJ, Li Y, et al. Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the Children’s Oncology Group. JAMA Oncol 2021;7(9):1313-21. PMID 34292305
56: Li J, Zhao S, Lee M, et al. Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma. Sci Adv 2020;6(42):eabb5427. PMID 33067228
57: Louis DN, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007;114(2):97-109. PMID 17618441
58: Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2015;1-18. PMID 27157931
59: Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23(8):1231-51. PMID 34185076
60: MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52. PMID 11544480
61: Marymont MH, Geohas J, Tomita T, Strauss L, Brand WN, Mittal BB. Hyperfractionated craniospinal radiation in medulloblastoma. Pediatr Neurosurg 1996;24:178-84. PMID 8873159
62: Mastrangelo R, Lasorella A, Riccardi R, et al. Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an "up front" study. Med Pediatr Oncol 1995;24:188-96. PMID 7838041
63: Michalski JM, Janss AJ, Vezina LG, et al. Children's Oncology Group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2021;39(24):2685-97. PMID 34110925
64: Misaki K, Hayashi Y, Minamoto T, et al. Correlation of gamma-catenin expression with good prognosis in medulloblastomas. J Neurosurg 2005;102:197-206. PMID 16156230
65: Nageswara Rao AA, Wallace DJ, Billups C, Boyett C, Gajjar A, Packer RJ. Cumulative cisplatin dose is not associated with event free or overall survival in children with newly diagnosed average risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the children’s oncology group. Pediatr Blood Cancer 2014;61(1):102-6. PMID 23956184
66: Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature 2017;547(7663):311-7. PMID 28726821
67: Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29(11):1408-14. PMID 20823417
68: Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012;488(7409):49-56. PMID 22832581
69: Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006:24(25):4202-8. PMID 16943538
70: Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 1999;17:2127-36. PMID 10561268
71: Packer RJ, Sutton LN, Atkins TE, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 1989;70:707-13. PMID 2709111
72: Packer RJ, Sutton LN, D'Angio G, Evans AE, Schut L. Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. Pediatr Neurosci 1986;12(4-5):272-82. PMID 3039477
73: Packer RJ, Sutton LN, Rorke LB, et al. Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 1984;61:296-301. PMID 6737054
74: Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma treated with radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro Oncol 2013;15(1):97-103. PMID 23099653
75: Pai Panandiker A, Ning H, Likhacheva A, et al. Craniospinal irradiation with spinal IMRT to improve target homogeneity. Int J Radiat Oncol Biol Phys 2007;68(5):1402-9. PMID 17467921
76: Park AK, Lee JY, Cheong H, et al. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. BMC Cancer 2019;19(1):571. PMID 31185958
77: Parker W, Filion E, Roberge D, Freeman CR. Intensity-modulated radiotherapy for craniospinal irradiation: target volume considerations, dose constraints, and competing risks. Int J Radiation Oncol Biol Phys 2007;69(1):251-7. PMID 17707279
78: Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011;331:435-9. PMID 21163964
79: Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27(10):1627. PMID 19255330
80: Pietsch T, Schmidt R, Remke M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol 2014;128(1): 137-49. PMID 24791927
81: Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415(6870):436-42. PMID 11807556
82: Prados MD, Edwards SB, Chang SM, et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a phase 2 study. Int J Radiat Oncol Biol Phys 1999;43:279-85. PMID 10030250
83: Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012;488(7409):106-10. PMID 22820256
84: Ramaswamy V, Remke M, Adamski J, et al. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro Oncol 2016;18(2):291-7. PMID 25605817
85: Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 2013;14(12):1200-7. PMID 24140199
86: Ramaswamy V, Remke M, Shih D, et al. Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer 2014;61:1190-4. PMID 24616042
87: Read TA, Hegedus B, Wechsler-Reya R, Gutmann DH. The neurobiology of neuro-oncology. Ann Neurol 2006;6:3-11. PMID 16802285
88: Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group. J Neurosurg 2006;105:444-51. PMID 17184075
89: Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: results from phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol 2015;33(24):2646-54. PMID 26169613
90: Robinson GW, Rudneva VA, Buchhalter I, et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 2018;19(6):768-84. PMID 29778738
91: Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 1983;42:1-5. PMID 6296325
92: Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005;352:978-86. PMID 15758008
93: Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010;28(33):4961-8. PMID 20940197
94: Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 2012;123:501-13. PMID 22139329
95: Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 2017;18(7):958-71. PMID 28545823
96: Sethi RV, Giantsoudi D, Raiford M, et al. Patterns of failure after proton therapy in medulloblastoma; linear energy transfer distributions and relative biological effectiveness associations for relapses. Int J Radiat Oncol Biol Phys 2014;88(3):655-63. PMID 24521681
97: Sharma T, Schwalbe EC, Williamson D, et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of group 3 and group 4 subtypes. Acta Neuropathol 2019;138(2):309-26. PMID 31076851
98: Shou Y, Robinson DM, Amakye DD, et al. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res 2015;21(3):585-93. PMID 25473003
99: Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome–associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Onc 2014;32(36):4155-61. PMID 25403219
100: Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 2016;164(5):1060-72. PMID 26919435
101: Sung KW, Yoo KH, Cho EJ, et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007;48(4):408-15. PMID 17066462
102: Takei H, Nguyen Y, Mehta V, Chintagumpala M, Dauser RC, Adesina AM. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation. J Neurosurg Pediatr 2009;3(1):61. PMID 19119907
103: Tamayo P, Cho YJ, Tsherniak A, et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol 2011;29(11):1415-23. PMID 21357789
104: Tarbell NJ, Loeffler J, Silver B, et al. The change in patterns of relapse in medulloblastoma. Cancer 1991;66:1600-4. PMID 1893359
105: Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123:465-71. PMID 22134537
106: Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 2003;21(8);1581-91. PMID 12697884
107: Taylor RE, Bailey CC, Robinson KJ, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 2005;41:727-34. PMID 15763649
108: Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuroaxis irradiation. J Clin Oncol 2000;18(16):3004-11. PMID 10944134
109: Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 2016;17(4):484-95. PMID 26976201
110: Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24(12):1924. PMID 16567768
111: Thorarinsdottir HK, Rood B, Kamani N, et al. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007;48(3):278-84. PMID 16456857
112: Thust SC, Blanco E, Michalski AJ, et al. MRI abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high‐dose thiotepa for high‐risk primitive neuroectodermal tumours of the central nervous system. J Med Imaging Radiat Oncol 2014;58(6): 683-90. PMID 25224299
113: Tonn S, Korshunov A, Obrecht D, et al. Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups. Neuro Oncol 2023;25(8):1518-29. PMID 36715306
114: Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med 1994;330:892-5. PMID 8114859
115: Wang X, Dubuc AM, Ramaswamy V, et al. Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropath 2015;129(3): 449-57. PMID 25689980
116: Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018;19(6):785-98. PMID 29753700
117: Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol 2016;17(3):287-98. PMID 26830377
118: Zeltzer P, Boyett J, Finlay J, et al. Prognostic factors for survival differ in high-risk intra- and supratentorial primitive neuroectodermal tumors. Pediatr Neurosurg 1993;19:333.
119: Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 2015;373(24):2336-46. PMID 26580448
120: Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013;31(23):2927-35. PMID 23835706
121: Zimmerman RA, Gusnard DA, Bilaniuk LB. Gadolinium DTPA enhanced MR evaluation of pediatric brain tumors. In: Packer RJ, Bleyer WA, Pochedly C, editors. Pediatric neuro-oncology: new trends in clinical research, (monographs in clinical pediatrics, vol 3). Philadelphia: Harwood Publ, 1992:42-76.

Patient Profile

Age range of presentation: 1 month to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Medulloblastoma: 191.6
ICD-10: Medulloblastoma: C71.6
ICD-O: Medulloblastoma, not otherwise specified: M9470/3

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Medulloblastoma

Associated Disorders

Neurofibromatosis
Nevoid basal cell carcinoma syndrome
Turcot syndrome

Differential Diagnosis

other posterior fossa tumors
cerebellar astrocytomas
brainstem gliomas in childhood
ependymomas
postviral cerebellar ataxia
- postviral cerebellitis
- drug ingestion
- posterior fossa abscess

Also Relevant

Brainstem gliomas in childhood
Cerebellar mutism
Dysplastic gangliocytoma of the cerebellum
Ependymoma
Molecular diagnosis of brain tumors
- Neurofibromatosis 1 and intracranial neoplasms of childhood
- Rare brain embryonal tumors in infacy and early childhood
- Turcot syndrome

Medulloblastoma …

Medulloblastoma

Introduction

Overview

Historical note and terminology

Table 1. Medulloblastoma

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 2. Simplified Biological Stratification of Medulloblastoma (105; 97)

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Tumors of the skull base

Breath-holding spells

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Ganglioglioma

Paraneoplastic syndromes

Medulloblastoma

Introduction

Overview

Historical note and terminology

Table 1. Medulloblastoma

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 2. Simplified Biological Stratification of Medulloblastoma (105; 97)

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Media

References

Contributors

Author

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Tumors of the skull base

Breath-holding spells

Acute cerebellar ataxia in children

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Ganglioglioma

Paraneoplastic syndromes

This is an article preview.
Start a Free Account
to access the full version.